CF Foundation Invests $3M to Support Phage Therapy, AP-PA02

The Cystic Fibrosis (CF) Foundation has invested $3 million in Armata Pharmaceuticals to support development of AP-PA02, a bacteriophage now being evaluated in a clinical trial for its ability to treat respiratory infections caused by Pseudomonas aeruginosa in people with cystic fibrosis (CF). ӗe are pleased by this investment by the CF Foundation as we [ŝThe post CF Foundation Invests $3M to Support Phage Therapy, AP-PA02 appeared first on Cystic Fibrosis News Today